HUP0300329A2 - Malonaminsavak és származékai és alkalmazásuk pajzsmirigy receptor ligandumként és ezeket tartalmazó gyógyszerkészítmények előállítására - Google Patents

Malonaminsavak és származékai és alkalmazásuk pajzsmirigy receptor ligandumként és ezeket tartalmazó gyógyszerkészítmények előállítására

Info

Publication number
HUP0300329A2
HUP0300329A2 HU0300329A HUP0300329A HUP0300329A2 HU P0300329 A2 HUP0300329 A2 HU P0300329A2 HU 0300329 A HU0300329 A HU 0300329A HU P0300329 A HUP0300329 A HU P0300329A HU P0300329 A2 HUP0300329 A2 HU P0300329A2
Authority
HU
Hungary
Prior art keywords
group
cra
alkyl
formula
crc
Prior art date
Application number
HU0300329A
Other languages
English (en)
Inventor
Gary Erik Aspnes
Yuan-Ching Phoebe Chiang
Kimberly Gail Estep
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0300329A2 publication Critical patent/HUP0300329A2/hu
Publication of HUP0300329A3 publication Critical patent/HUP0300329A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

A találmány szerinti vegyületek (I) általános képletében W jelentése -O-, -S-, -SO-, -SO2-, -CH2-, -CF2-, -CHF-, -C(O)-, -CH(OH)-, -NRa-vagy (a) képletű csoport, R0 jelentése, hidrogénatom, adott esetbenszubsztituált 1-6 szénatomos alkilcsoport, ahol a szubsztituens 3-6szénatomos cikloalkilcsoport, heterocikloalkilcsoport vagyfenilcsoport, amely adott esetben szubsztituálva lehet; R1, R2, R3 ésR6 jelentése egymástál függetlenül hidrogénatom, halogénatom, 1-8szénatomos alkilcsoport, -CF3, -OCF3, 1-8 szénatomos alkoxicsoportvagy cianocsoport, R4 jelentése adott esetben legfeljebb háromszubsztituenssel szubsztituált 1-12 szénatomos alkilcsoport; R3 és R4jelentése a kapcsolódó szénatomokkal együtt -(CH2)i- képletűkarbociklusos gyűrű vagy -(CH2)k-Q-(CH2)l- képletű heterociklusosgyűrű, ahol Q jelentése -O-, -S- vagy -NRe-, i értéke 3, 4, 5 vagy 6,k értéke 0, 1 , 2, 3, 4 vagy 5, l értéke 0, 1 , 2, 3, 4 vagy 5, ésahol a karbociklusos gyűrű vagy a heterociklusos gyűrű adott esetbenlegfeljebb négy szubsztituenssel szubsztituálva lehet, R5 jelentésehidroxilcsoport, 1-6 szénatomos alkoxicsoport, -OC(O)Rf, F vagy -C(O)ORc, vagy R4 és R5 jelentése a kapcsolódó szénatomokkal együtt -CRc=CRa-NH-, -N=CRa-NH-, -CRc=CRa-O-, -CRc=CRa-S-, -CRc=N-NH- vagy -CRa=CRa-CRa=N- képletű heterociklusos gyűrű, R7 jelentése hidrogénatomvagy 1-6 szénatomos alkilcsoport, R8 és R9 jelentése egymástólfüggetlenül hidrogénatom, 1-6 szénatomos alkilcsoport, arilcsoportvagy (d) halogénatom, R10 jelentése -(0-1 szénatomos alkil)-C(O)OH, -(0-1 szénatomos alkil)-C(O)-ORf, -(0-1 szénatomos alkil)C(O)NRcRdvagy-(0-1 szénatomos alkil)-OH csoport. A találmány kiterjed a fentivegyületek alkalmazására gyógyszerkészítmények előállításánál. Ó
HU0300329A 2000-03-31 2001-03-07 Malonamic acids and derivatives and use thereof as thyroid receptor ligands and for preparation of pharmaceutical compositions containing them HUP0300329A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19361800P 2000-03-31 2000-03-31
PCT/IB2001/000317 WO2001072692A1 (en) 2000-03-31 2001-03-07 Malonamic acids and derivatives thereof as thyroid receptor ligands

Publications (2)

Publication Number Publication Date
HUP0300329A2 true HUP0300329A2 (hu) 2003-07-28
HUP0300329A3 HUP0300329A3 (en) 2004-08-30

Family

ID=22714346

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300329A HUP0300329A3 (en) 2000-03-31 2001-03-07 Malonamic acids and derivatives and use thereof as thyroid receptor ligands and for preparation of pharmaceutical compositions containing them

Country Status (38)

Country Link
US (1) US20070173548A1 (hu)
EP (1) EP1268404B1 (hu)
JP (1) JP3866977B2 (hu)
KR (1) KR20020089420A (hu)
CN (1) CN1422246A (hu)
AP (1) AP2002002634A0 (hu)
AR (1) AR033516A1 (hu)
AT (1) ATE382602T1 (hu)
AU (1) AU2001237665A1 (hu)
BG (1) BG107036A (hu)
BR (1) BR0109625A (hu)
CA (1) CA2403902C (hu)
CR (1) CR6742A (hu)
CZ (1) CZ20023190A3 (hu)
DE (1) DE60132181D1 (hu)
DZ (1) DZ3276A1 (hu)
EA (1) EA200200921A1 (hu)
EE (1) EE200200566A (hu)
GT (1) GT200100041A (hu)
HK (1) HK1052498A1 (hu)
HU (1) HUP0300329A3 (hu)
IL (1) IL151376A0 (hu)
IS (1) IS6516A (hu)
MA (1) MA26886A1 (hu)
MX (1) MXPA02009702A (hu)
NO (1) NO20024639L (hu)
NZ (1) NZ520660A (hu)
OA (1) OA12237A (hu)
PA (1) PA8513801A1 (hu)
PE (1) PE20011186A1 (hu)
PL (1) PL358596A1 (hu)
SK (1) SK13762002A3 (hu)
SV (1) SV2002000357A (hu)
TN (1) TNSN01048A1 (hu)
TR (1) TR200202249T2 (hu)
WO (1) WO2001072692A1 (hu)
YU (1) YU74102A (hu)
ZA (1) ZA200207444B (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
ES2242723T3 (es) * 2000-02-17 2005-11-16 Bristol-Myers Squibb Company Ligandos derivados de anilina para el receptor de la tiroides .
EP1347959A1 (de) * 2000-12-27 2003-10-01 Bayer Aktiengesellschaft Indol-derivate
GB2374009A (en) * 2001-02-12 2002-10-09 Novartis Ag Method of treating hair loss
CA2449515A1 (en) * 2001-08-24 2003-03-06 Karo Bio Ab Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
AU2004293013B2 (en) 2003-11-19 2011-04-28 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
GB0606201D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Improved crytalline material
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
EP2272817A4 (en) * 2008-04-11 2011-12-14 Inst Med Molecular Design Inc INHIBITOR OF PAI-1
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2346814A2 (en) 2008-10-27 2011-07-27 Cadila Healthcare Limited Thyroid receptor ligands
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010086878A2 (en) 2009-01-09 2010-08-05 Cadila Healthcare Limited Thyroid receptor modulators
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2528392T3 (es) 2012-08-06 2015-02-09 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Eprotiroma para su uso en la prevención y/o tratamiento de trastornos capilares y composiciones de la misma
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US20170112741A1 (en) * 2014-04-09 2017-04-27 Goldcrest Medicine Institute Co., Ltd. Agent for ameliorating skin symptom, hair growth agent or slimming agent
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
BR112019025659A2 (pt) 2017-06-05 2020-08-25 Viking Therapeutics, Inc. composições para o tratamento de fibrose
CN107474007B (zh) * 2017-08-28 2019-04-19 上海再启生物技术有限公司 一种制备3，6-二羟基苯二甲酰亚胺的方法
JP2021518403A (ja) 2018-03-22 2021-08-02 バイキング・セラピューティクス・インコーポレイテッド 化合物の結晶形態及び化合物の結晶形態を生成する方法
TW202115029A (zh) * 2019-07-31 2021-04-16 大陸商深圳微芯生物科技股份有限公司 雜環化合物及其用途
EP3878837A1 (en) * 2020-03-11 2021-09-15 OM Pharma SA 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069343A (en) * 1973-03-23 1978-01-17 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4554290A (en) * 1983-06-17 1985-11-19 Ciba-Geigy Corporation Oxamic acid derivatives
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5061798A (en) * 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
US5232947A (en) * 1988-07-04 1993-08-03 Meiji Seika Kaisha, Ltd. Oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
DE69314718T2 (de) * 1992-07-21 1998-02-26 Ciba Geigy Ag Oxamidsäure-Derivate als hypocholesterämische Mittel
CO5160290A1 (es) * 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
WO2000072812A1 (en) * 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylether derivatives
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands

Also Published As

Publication number Publication date
IL151376A0 (en) 2003-04-10
EP1268404B1 (en) 2008-01-02
TNSN01048A1 (fr) 2005-11-10
CR6742A (es) 2003-11-25
AP2002002634A0 (en) 2002-09-30
CA2403902A1 (en) 2001-10-04
NO20024639D0 (no) 2002-09-27
MXPA02009702A (es) 2003-03-27
HUP0300329A3 (en) 2004-08-30
WO2001072692A1 (en) 2001-10-04
SK13762002A3 (sk) 2004-01-08
OA12237A (en) 2003-10-23
DE60132181D1 (de) 2008-02-14
BG107036A (bg) 2003-04-30
JP2003528847A (ja) 2003-09-30
PL358596A1 (en) 2004-08-09
HK1052498A1 (zh) 2003-09-19
EA200200921A1 (ru) 2003-02-27
BR0109625A (pt) 2003-04-22
PE20011186A1 (es) 2001-11-15
GT200100041A (es) 2002-03-22
AU2001237665A1 (en) 2001-10-08
ATE382602T1 (de) 2008-01-15
DZ3276A1 (fr) 2001-10-04
YU74102A (sh) 2006-03-03
TR200202249T2 (tr) 2003-01-21
AR033516A1 (es) 2003-12-26
US20070173548A1 (en) 2007-07-26
JP3866977B2 (ja) 2007-01-10
KR20020089420A (ko) 2002-11-29
CZ20023190A3 (cs) 2003-10-15
ZA200207444B (en) 2003-09-17
EP1268404A1 (en) 2003-01-02
MA26886A1 (fr) 2004-12-20
CN1422246A (zh) 2003-06-04
EE200200566A (et) 2004-06-15
NO20024639L (no) 2002-09-27
IS6516A (is) 2002-08-21
CA2403902C (en) 2007-04-24
NZ520660A (en) 2004-03-26
SV2002000357A (es) 2002-07-16
PA8513801A1 (es) 2002-02-21

Similar Documents

Publication Publication Date Title
HUP0300329A2 (hu) Malonaminsavak és származékai és alkalmazásuk pajzsmirigy receptor ligandumként és ezeket tartalmazó gyógyszerkészítmények előállítására
HUP0400691A2 (hu) Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
HUP0104816A2 (hu) 3-Azabiciklo[3.1.0]hexán-származékok mint ópiát receptor ligandumok és eljárás előállításukra
ATE49763T1 (de) 1h-imidazo(4,5c)chinoline und 1h-imidazo(4,5c)chinolin-4-amine.
HUP0300565A2 (hu) PDE 5 inhibitor hatású 8-kinolin-xantin- és 8-izo-kinolin-xantin-származékok, alkalmazásuk, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0002112A2 (hu) Helyettesített 3-ciano-kinolinok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
HUP0203895A2 (hu) Szubsztituált azaindolok és ilyen vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0202810A2 (hu) Szubsztituált 2-tio-3.5-diciano-4-aril-6-aminopiridinek és eljárás az előállításukra, valamint ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NZ512731A (en) Tricyclic inhibitors of poly(ADP-ribose) polymerases
HUP0302480A2 (hu) Piridinonszármazékok ateroszklerózis kezelésére, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények
MXPA04000532A (es) Derivados de 8-metoxi-(1,2,4)-triazolo(1,5-a)piridina y su uso como ligandos receptores de adenosina.
HUP9802937A2 (hu) Benzo[g]kinolin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
HUP0402235A2 (hu) 4,4-Difluor-1,2,3,4-tetrahidro-5H-1-benzazepin-származékok és ezek sói és ezeket tartalmazó gyógyszerkészítmények
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
SE8106733L (sv) 2-substituerade bensofuran-derivat och forfarande for deras framstellning
HUP0004020A2 (hu) Triciklusos triazolo-benzazepin-származékok, eljárás a vegyületek előállítására és alkalmazásuk antiallergiás szerként
HUP0400317A2 (hu) Béta-karbolin származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
ES8401034A1 (es) Derivados de quinolina.
NO922148L (hu)
HUP0301587A2 (hu) Foszfodiészteráz V gátló hatású 5-amino-alkil-pirazolo[4,3-d]pirimidinek, ezeket tartalmazó gyógyszerkészítmények és eljárások az elżállításaikra
HUP0303457A2 (hu) Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk
ES8105976A1 (es) Procedimiento para la preparacion de acilureas
ES8203867A1 (es) Procedimiento para la obtencion de derivados de benzotiazol
HUP0102522A2 (hu) 3',3'-N-bisz-helyettesített makrolid LHRH antagonista vegyületek és alkalmazásuk, eljárás előállításukra, valamint e vegyületeket tartalmazó gyógyászati készítmények
HUP9903526A2 (hu) Pirimidinszármazékok és az ezeket tartalmazó gyógyszerkészítmények